Ad-hoc Publications

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

2014

September 18, 2014Strategic corporate decision:
Bayer plans to focus entirely on Life Science businesses
Download ( PDF, 29 KB ) collect
September 18, 2014Strategic corporate decision:
Bayer Board of Management plans to focus entirely on Life Science businesses
Download ( PDF, 27 KB ) collect

2013

No Ad-hoc Messages were issued in year 2013.

2012

No Ad-hoc Messages were issued in year 2012.

2011

September 29, 2011
Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy EndpointDownload ( PDF, 87 KB ) collect
September 6, 2011
Bayer AG: FDA has published documents for discussion at the Advisory Committee on the new drug application for RivaroxabanDownload ( PDF, 124 KB ) collect

2010

October 31, 2010
Bayer AG: Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. WarfarinDownload ( PDF, 41 KB ) collect
August 4, 2010
Bayer AG: Rivaroxaban Meets Primary Endpoint in Long-Term Phase III EINSTEIN-DVT StudyDownload ( PDF, 37 KB ) collect

2009

September 15, 2009Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010Download ( PDF, 35 KB ) collect

2008

March 3, 2008Bayer AG: Court Decides against the Company’s Yasmin® Patent Download ( PDF, 36 KB ) collect

2007

April 26, 2007Bayer exceeds consensus estimates for Q1 2007Download ( PDF, 63 KB ) collect

Previous ad-hoc publications can be found in the Archive.

Last updated: September 18, 2014 Copyright © Bayer AG